Poetry NewsSep 5, 2023

Muvalaplin
Effective, lowers levels
Clinical trial success
Lipoprotein(a) addressed
Breakthrough

#muvalaplin #clinicaltrial #lipoproteina #breakthrough #cinquain #poetry

http://www.medicalnewstoday.com/articles/first-oral-drug-for-genetic-bad-cholesterol-lowers-levels-by-over-50-in-clinical-trial

First oral drug for genetic bad cholesterol lowers levels by over 50% in clinical trial

In a phase 1 clinical trial, the experimental drug muvalaplin successfully lowered the levels of a previously untreatable form of bad cholesterol, lipoprotein(a).

Medical News Today
Matt WillemsenSep 2, 2023
A “Silent Killer” With No Treatment – Scientists Develop Game-Changing Drug
A new oral drug, Muvalaplin, successfully lowers Lipoprotein(a) or Lp(a), a genetic form of cholesterol linked to heart attack and stroke, by up to 65%, marking a significant breakthrough as there is currently no approved treatment for high Lp(a) levels.
https://scitechdaily.com/a-silent-killer-with-no-treatment-scientists-develop-game-changing-drug/ #Cholesterol #Drugs #HeartAttack #Muvalaplin #Lipoprotein(a)
A “Silent Killer” With No Treatment – Scientists Develop Game-Changing Drug

A new drug presents the world's first treatment for Lipoprotein(a), a predominantly genetic type of cholesterol that elevates the risk of cardiac arrest or stroke. Professor Stephen Nicholls, Director of the Victorian Heart Institute and Victorian Heart Hospital at Monash University, recently annou

SciTechDaily